<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04277377</url>
  </required_header>
  <id_info>
    <org_study_id>2020-00295</org_study_id>
    <nct_id>NCT04277377</nct_id>
  </id_info>
  <brief_title>Nanoparticle for DSA Removal</brief_title>
  <official_title>Donor-specific Anti-human Leukocyte Antigen Antibodies (DSA) Re-moval From Patient Blood Using Functionalized Nanoparticles - an ex Vivo Feasibility and Proof of Principle Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Magnetic nanoparticles, coated with human leukocyte antigens (HLA) to capture anti-HLA
      antibodies with donor specificity (donor-specific antibodies, DSA), will be tested ex-vivo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project aims at developing a new method using human leukocyte antigens (HLA)-coated
      magnetic nanoparticles to remove donor-specific antibodies (DSA) from the patients' blood ex
      vivo, while trying to keep the blood unaffected after exposure to the particles.

      Nanoparticles will be engineered and tested ex vivo. While nanoparticles were successfully
      coated with macromolecules such as antibodies in the past, this is a new approach, which will
      be performed by the research group.

      The goal of this project is to capture DSA in patient blood ex vivo and to remove them by
      magnetic separation. Efficacy and safety of this procedure will be assessed, especially the
      interaction of these novel particles with other blood components such as coagulation factors
      or effector cells, which could produce inflammatory mediators. According analyses are
      initiated and carried out.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of DSA removed in a blood sample using HLA-coated magnetic nanoparticles</measure>
    <time_frame>1 day</time_frame>
    <description>Quantification of DSA removal using HLA-coated magnetic nanoparticles in comparison with blood treated with control nanoparticles (without HLA coating).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood coagulation (rotational thromboelastometry ROTEM, plasma clotting time) before and after treatment with HLA-coated magnetic nanoparticles</measure>
    <time_frame>1 day</time_frame>
    <description>Coagulation parameters as described will be evaluated in blood samples. The same analyses will be repeated after exposure to HLA-coated magnetic nanoparticles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory blood mediators (IL-6, MCP-1) before and after treatment with HLA-coated magnetic nanoparticles</measure>
    <time_frame>1 day</time_frame>
    <description>Inflammatory parameters as described will be evaluated in blood samples. The same analyses will be repeated after exposure to HLA-coated magnetic nanoparticles.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Kidney Failure</condition>
  <condition>Presence of Donor Specific Antibodies</condition>
  <arm_group>
    <arm_group_label>DSA in patients with kidney failure</arm_group_label>
    <description>Patients on kidney transplantation waiting list with DSA detected by Luminex (and mean fluorescence intensity (MFI) &gt; 1000) in their blood.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Bloodsample
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients suffering from kidney failure with DSA.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DSA in the blood as detected by Luminex®

          -  Adults (&gt;18 years old)

          -  Informed written consent

        Exclusion Criteria:

          -  Inability to follow the procedures of the study, due to language problems,
             psychological disorders, social conditions or dementia

          -  Pregnancy and/or breast feeding

          -  Unwillingness to participate in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beatrice Beck Schimmer, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beatrice Beck Schimmer, Prof</last_name>
    <phone>+41442552696</phone>
    <phone_ext>+41442552696</phone_ext>
    <email>beatrice.beck@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martin Schläpfer, PD</last_name>
    <phone>+41442554690</phone>
    <phone_ext>+41442552696</phone_ext>
    <email>martin.schlaepfer@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Zurich, Division of Anaesthesiology</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Wan SS, Ying TD, Wyburn K, Roberts DM, Wyld M, Chadban SJ. The Treatment of Antibody-Mediated Rejection in Kidney Transplantation: An Updated Systematic Review and Meta-Analysis. Transplantation. 2018 Apr;102(4):557-568. doi: 10.1097/TP.0000000000002049.</citation>
    <PMID>29315141</PMID>
  </reference>
  <reference>
    <citation>Herrmann IK, Beck-Schimmer B, Schumacher CM, Gschwind S, Kaech A, Ziegler U, Clavien PA, Günther D, Stark WJ, Graf R, Schlegel AA. In vivo risk evaluation of carbon-coated iron carbide nanoparticles based on short- and long-term exposure scenarios. Nanomedicine (Lond). 2016 Apr;11(7):783-96. doi: 10.2217/nnm.16.22. Epub 2016 Mar 16.</citation>
    <PMID>26979124</PMID>
  </reference>
  <reference>
    <citation>Jacobson M, Roth Z'graggen B, Graber SM, Schumacher CM, Stark WJ, Dumrese C, Mateos JM, Aemisegger C, Ziegler U, Urner M, Herrmann IK, Beck-Schimmer B. Uptake of ferromagnetic carbon-encapsulated metal nanoparticles in endothelial cells: influence of shear stress and endothelial activation. Nanomedicine (Lond). 2015;10(24):3537-46. doi: 10.2217/nnm.15.172. Epub 2015 Oct 5.</citation>
    <PMID>26434758</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 13, 2020</study_first_submitted>
  <study_first_submitted_qc>February 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2020</study_first_posted>
  <last_update_submitted>February 17, 2020</last_update_submitted>
  <last_update_submitted_qc>February 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Donor specific antibodies</keyword>
  <keyword>Kidney transplantation</keyword>
  <keyword>Coated nanoparticles</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

